Scholarlink

<p>Overexpression of Sxc-, a cystine/glutamate antiporter is implicated in several neurological disorders including epilepsy. Physiologically, it regulates the hippocampal synaptic glutamate pool, influencing the neuronal excitability. Sulfasalazine (SAS) recently garnered interest owing to its system xc- (Sxc-) inhibitory potential. Therefore, the current study investigated the effects of SAS in two distinct models, (i) maximal electroshock (MES) induced acute seizure model and (ii) Pentylenetetrazol (PTZ) induced kindling model of chronic epilepsy and associated cognitive impairment. Initially, rats treated with different doses of SAS (25- 200&#xa0;mg/kg, i.p.) for 7 days were subjected to MES and observed for seizures. SAS 50&#xa0;mg/kg improved the extension-to-flexion ratio (E/F ratio) in MES induced seizures and exhibited neuroprotection, whereas the higher doses failed. In another experiment, mice were treated with PTZ (35&#xa0;mg/kg) on alternate days for 24 days to induce kindling. SAS (50 or 100&#xa0;mg/kg, i.p.) or vehicle was administered daily, 30&#xa0;min prior to each PTZ injection. Seizures were monitored for 30&#xa0;min following PTZ injection. Chronic PTZ administration led to progressively increased seizure severity, culminating in generalized tonic-clonic seizures in mice. SAS 100 mg/kg treatment reduced stage 4 and 5 seizure scores and improved spatial retention memory in mice. SAS also significantly attenuated the gene expression of inflammatory cytokines, TNF-α, IL-1β, and IL-6, and mitigated neuronal damage induced by epileptic kindling. Altogether, results suggest that SAS exhibits anti-epileptic effects, reduces neuroinflammation, and alleviates cognitive dysfunction in the PTZ kindling model of epilepsy in mice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroprotective effects of sulfasalazine in experimental model of seizures and epilepsy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Sree Lalitha Bojja,
  • Gangadhar Hari,
  • Ilora Bandyopadhyay,
  • Kiran Kumar Kolathur,
  • Mallikarjuna Rao Chamallamudi

摘要

Overexpression of Sxc-, a cystine/glutamate antiporter is implicated in several neurological disorders including epilepsy. Physiologically, it regulates the hippocampal synaptic glutamate pool, influencing the neuronal excitability. Sulfasalazine (SAS) recently garnered interest owing to its system xc- (Sxc-) inhibitory potential. Therefore, the current study investigated the effects of SAS in two distinct models, (i) maximal electroshock (MES) induced acute seizure model and (ii) Pentylenetetrazol (PTZ) induced kindling model of chronic epilepsy and associated cognitive impairment. Initially, rats treated with different doses of SAS (25- 200 mg/kg, i.p.) for 7 days were subjected to MES and observed for seizures. SAS 50 mg/kg improved the extension-to-flexion ratio (E/F ratio) in MES induced seizures and exhibited neuroprotection, whereas the higher doses failed. In another experiment, mice were treated with PTZ (35 mg/kg) on alternate days for 24 days to induce kindling. SAS (50 or 100 mg/kg, i.p.) or vehicle was administered daily, 30 min prior to each PTZ injection. Seizures were monitored for 30 min following PTZ injection. Chronic PTZ administration led to progressively increased seizure severity, culminating in generalized tonic-clonic seizures in mice. SAS 100 mg/kg treatment reduced stage 4 and 5 seizure scores and improved spatial retention memory in mice. SAS also significantly attenuated the gene expression of inflammatory cytokines, TNF-α, IL-1β, and IL-6, and mitigated neuronal damage induced by epileptic kindling. Altogether, results suggest that SAS exhibits anti-epileptic effects, reduces neuroinflammation, and alleviates cognitive dysfunction in the PTZ kindling model of epilepsy in mice.